Beyond the Data: The Strategic Role of Clinical Outcome Assessments in Regulatory Success
Demonstrating safety and efficacy is only part of the equation in regulated research. The other—often harder—part is showing that your intervention truly improves patients’ lives. That’s where Clinical Outcome Assessments (COAs) come in.
What Are COAs and Why Do They Matter?
COAs are tools used to measure a patient’s health condition and treatment benefit in clinical trials. These assessments can be reported directly by patients (PROs), clinicians (ClinROs), observers (ObsROs), or through performance-based measures (PerfOs). They’re critical in capturing meaningful outcomes like pain reduction, mobility improvement, or better sleep—that biomarkers alone can’t tell us.
The FDA defines COAs as measures that describe or reflect how a patient feels, functions, or survives. They are central to patient-focused drug development and can support labeling claims when integrated effectively into a trial’s design.
Strategic Value in Regulatory Submissions
The FDA’s Clinical Outcome Assessment Compendium and related FAQ resources offer transparency on how COAs have been used in past approvals. While inclusion in the compendium or qualification under the FDA’s COA Qualification Program can be helpful, it’s not a requirement. COAs can be used outside the qualification program, provided they are well-justified and fit-for-purpose.
BSC’s Approach to Maximizing COA Impact
At BSC®, we help sponsors go beyond compliance:
- Select Fit-for-Purpose COAs: We identify validated or context-appropriate COAs that match your therapeutic area and trial objectives.
- Design for Defensibility: Our trial designs integrate COAs with robust statistical planning, ensuring endpoints are scientifically credible and aligned with FDA expectations.
- Navigate Regulatory Advice Pathways: Whether through the CDER COA Qualification Program or individual development consultations, we help you engage the FDA early and strategically.
What’s at Stake?
Your choice of COA can define the credibility of your trial’s outcomes. A well-chosen COA can bridge clinical data and meaningful patient benefits—critical for regulatory approval and real-world adoption.
Need support choosing or implementing the right COA? Let BSC® guide you through COA strategy and endpoint design with the expertise and precision your trial demands.
Congratulations to BSC®’s David Maislin, Alex Breno, and our friends at 3Spine on their recent publication!
The article lays out the protocol for the pivotal IDE trial behind 3Spine's MOTUS® lumbar Total Joint Replacement, the first device built to restore both disc and facet joint function without sacrificing motion.
WHAT CLIENTS SAY
“They listen the first time. I’ve never had to go back and respell out what I needed."
”They work to understand the problem and leverage the information that is already there.”
Former FDA Regulator
WHAT CLIENTS SAY
"Battle ground tested."
"There is nothing that David and team haven’t seen over the years – the good, bad, and ugly.”
Vice President, Clinical Operations
WHAT CLIENTS SAY
"Get stuff done when you have to do something no one else has done before."
"They aren’t afraid to tackle difficult scenarios in compressed timelines."
CEO, Medical Device Company
Regulatory-first biostatistics
Support built specifically for FDA-facing programs, from early feasibility through submission and post-market requirements.
Direct communication, faster turn around
Our biostatisticians write the SAP and run the analysis. One person owns both — no separate programmer, no project manager in between.
Versatile Solutions
Engage us for a focused analysis or a full submission, We size the work to the problem.
Proven FDA Experience
Hands-On Experience with FDA Pathways, statistical reviews, and regular interactions, reducing risk and rework.